EAGAN, Minn., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug ...
MINNEAPOLIS, June 22, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), an AI-driven oncology and drug discovery company, announced today that two of their wholly owned subsidiaries, ...
MINNEAPOLIS, April 16, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) ("Precision" or "the Company") today announced that its wholly owned subsidiary, TumorGenesis, is ...
MINNEAPOLIS, April 09, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), formerly Skyline Medical, a company focused on applying artificial ...
MINNEAPOLIS, May 20, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), an artificial intelligence driven oncology and drug discovery company, announced today that its wholly owned ...
A Top US Medical Institution Places the First Commercial Order for the Media used to grow Ovarian Cancer Cell Types that are Exceedingly Difficult to Grow and Retain the Signatures of the Patient ...
* TESTING OF TUMORGENESIS PDX TUMORS TO TAKE PLACE IN COLLABORATION WITH HELOMICS, IN WHICH CO HAS 20% EQUITY STAKE * IN NEGOTIATIONS WITH MEDICAL TECHNOLOGY COS TO LICENSE THEIR TECHNOLOGY TO ...
* PRECISION THERAPEUTICS - LICENSE AGREEMENT WILL ADVANCE PLAN TO DEVELOP PATIENT DERIVED TUMOR MODELS FOR PRECISION CANCER THERAPY, DRUG DEVELOPMENT Source text for Eikon: Further company coverage: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results